Supplementary Table 3.

Results of the multivariable models for the two sensitivity analyses assessing the impact of oral hypoglycemic use post-NMIBC diagnosis

Models (n)	Post-NMIBC exposure, per year of use*	Disease-specific survival	Overall survival
		HR (95% CI)	HR (95% CI)
Sensitivity analysis #1 (n=2092)†	Metformin	1.1 (0.93–1.2)	0.96 (0.92–1.0)
	Glyburide	1.26 (1.1–1.4)	1.0 (0.97–1.1)
	Thiazolidinedione	0.55 (0.24–1.3)	0.92 (0.78–1.1)
	Other oral anti-diabetic agents	0. 81 (0.49–1.3)	1.0 (0.94–1.2)
	Insulin	1.3 (0.84–1.9)	1.1 (0.98–1.2)
Sensitivity analysis #2 (n=1222)‡	Metformin	0.95 (0.77–1.2)	0.93 (0.88–0.99)
	Glyburide	1.05 (0.81–1.4)	1.02 (0.96–1.09)
	Thiazolidinedione	0.73 (0.27–2.0)	1.07 (0.87–1.3)
	Other oral anti-diabetic agents	0.46 (0.15–1.4)	0.97 (0.85–1.1)
	Insulin	1.7 (1.1–2.4)	1.1 (0.87–1.3)

^*Models adjusted for year of diagnosis, age at non-muscle-invasive bladder cancer (NMIBC), time between DM and NMIBC diagnosis, gender, area of residency, neighbourhood income quintile, Charlson comorbidity score and baseline use of anti-diabetic agents.

^†Cohort composed of individuals included in the main cohort and including individuals who died within six months of NMIBC diagnosis.

^‡Cohort restricted to individuals diagnosed with DM and NMIBC after 1996.

CI: confidence interval; HR: hazard ratio.